All agreed loans

Denmark. Novozymes A/S

Date of agreement: 16 Jan 2020
Country: Denmark
Customer: Novozymes A/S
Amount in DKK: DKK 750 million
Amount in EUR: EUR 100.3 million
Maturity: 10 years
NACE sector / loan type: Research and development
Business area: Industries and services

Project

The loan will finance Novozymes research and development (R&D) activities in 2019.

The project includes R&D activities in bio-agriculture, household care as well as food and beverages platforms. The investments also involve general biotechnology research.

The total budget of the programme amounts to approximately DKK 1,874 million.

Approximately 13% of Novozymes’ revenue is reinvested into research annually. The company has more than 700 products in its portfolio and holds more than 6,500 active and pending patents.

This is NIB’s fifth loan agreement for Novozymes R&D investments.

Novozymes is a global biotechnology company with a strong focus on enzyme production. The company’s bio-solutions range from the removal of trans-fats in food to advancements in renewable energy sources. More than 23% of Novozymes' 6,000 employees work within research and development.

Fulfilment of NIB's mandate

Novozymes is one of the most R&D intensive companies in the Nordic-Baltic region, with an R&D to sales ratio of 13%, and new product to total sales ratio of 27%.

R&D into bio-agricultural products builds on Novozymes’ market leading product portfolio in animal health (feed enzymes and probiotics), biomass conversion (ethanol production solutions) and other biotech solutions in agriculture.

In the household care platform, the company focuses on improved freshness solutions in fabric detergents and more efficient use of water resources.

The innovations in the food and beverage platform will improve grain milling and vegetable oil processing. The new solutions should increase grinding capacity, starch output and energy efficiency, and improve the efficiency of vegetable oil refineries.

R&D investments are likely to have positive spill-over effects on other companies operating in the industry and in the region.

The company is collaborating with many Danish Universities and recently moved its R&D operations to a new centre on the Technical University of Denmark campus. This will further strengthen the cooperation and support the growth of the biotech cluster in Denmark.

Estimated impacts related to the investments:

  • R&D to sales ratio: 13%
  • Share of new products of total sales: 27%
  • R&D expenditures 2019: DKK 1874 million

Sustainability summary

No significant environmental risks identified in relation with Novozymes’ R&D projects.

Press release

NIB fortsætter med at finansiere Novozymes’ R&D-investeringer